Repriv Cardiovascular, Inc. announced this week that it has raised $42 million in Series A funding to advance clinical trials of automatic diuretics and fluid management treatments for acute decompensated heart failure (ADHF). The company said its technology helps reduce high readmission rates.

The round was co-led by Lightstone Ventures and Sante Ventures, with participation from Deerfield Management, Genesis Capital, and Arboretum Ventures. The funding will advance the company’s clinical programs, including the ongoing FASTR trial and future pivotal trials.

“Today, the standard of care for fluid removal in heart failure patients is diuretics. First approved 60 years ago, diuretics remain the primary treatment option, but are difficult to optimally dose without real-time patient information. Mark Pacyna, chief executive officer of Reprieve Cardiovascular, said in a statement to Health Imaging. Mr. Pasina previously served as Vice President and General Manager of Medtronics’ Peripheral Vascular Portfolio.

Reprieve’s technology aims to personalize decongestion management and safely, quickly, and completely remove excess body fluids to improve patient outcomes and prevent readmissions. The system monitors physiological parameters such as urine output to provide tailored diuretic dosing and hydration for ADHF patients, giving physicians and care teams visibility and control over their treatment.

“We are excited to share Reprieve’s story as the company emerges from stealth mode ahead of a pivotal trial,” Jan Garfinkle, founder and managing partner of Arboretum Ventures, said in a statement. Stated. “Series A funding strengthens the Reprieve team and our belief in the need for new technologies that can improve the lives of patients suffering from acute decompensated heart failure around the world.”

The company’s board of directors includes James Yudelson, M.D., chief of cardiology at Tufts University; Michael Jaff, DO, Boston Scientific Vice President of Clinical Affairs. Javed Butler, MD, Director, Baylor Scott & White Research Institute; Sean Collins, MD, director of the Vanderbilt Center for Emergency Medicine Research and Innovation; Julia Lewis, MD, professor, Vanderbilt Department of Nephrology and Hypertension; and Dr. Jeff Testani, director of heart failure research at Yale University.

6.7 or higher. Today, millions of Americans live with heart failure. [1] ADHF is caused by a rapid onset of body fluid volume overload. More than 1 million patients are hospitalized annually in the United States with a primary diagnosis of heart failure, and millions more worldwide, with an average length of stay of more than 5 days. [2,3] Nearly one in four patients will be readmitted for retreatment of volume overload within 30 days, and approximately half will return within 6 months. [4]